5 completed, 2 active not recruiting, 2 unknown, 1 recruiting. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 5, Active not recruiting 2, Unknown 2, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Tongue Diseases: new trials by email Literature Review of Tongue Diseases trials Research Report on Tongue Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Different Amoxicillin Treatment Regimens in Erythema Migrans Patients EM-amoxicillin 3 x 10 days, EM-amoxicillin 3 x 14 days, Controls - Erythema Migrans | Phase 3 | Recruiting | University Medical Centre Ljubljana | 200 | 2019-06-01 | 2026-03-25 |
| Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy doxepin hydrochloride, placebo - Head and Neck Cancer, Mucositis | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 155 | 2010-12-01 | 2017-08-09 |
| RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer cetuximab, intensity-modulated radiation therapy - Head and Neck Cancer | Phase 3 | Active not recruiting | Radiation Therapy Oncology Group | 702 | 2010-03-31 | 2026-01-06 |
| Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Pilocarpine, ALTENS - Head and Neck Cancer, Xerostomia | Phase 2 / Phase 3 | Completed | Radiation Therapy Oncology Group | 196 | 2008-09-01 | 2019-11-19 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Bevacizumab, Carboplatin, Cisplatin - Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 403 | 2008-08-08 | 2026-10-22 |
| PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer positron emission tomography/computed tomography, therapeutic conventional surgery - Head and Neck Cancer | Phase 3 | Unknown | Warwick Medical School | 560 | 2007-09-01 | 2013-08-26 |
| Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract therapeutic nutritional supplementation, placebo - Head and Neck Cancer, Infection | Phase 3 | Completed | Centre Antoine Lacassagne | 311 | 2007-07-01 | 2025-09-30 |
| GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer sargramostim, oral salt and soda mouthwash - Head and Neck Cancer, Mucositis Oral | Phase 3 | Completed | Marilyn Dodd | 91 | 2005-06-07 | 2021-07-30 |
| Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx aldesleukin, adjuvant therapy, conventional surgery - Head and Neck Cancer | Phase 3 | Unknown | European Institute of Oncology | 260 | 1992-09-01 | 2013-08-26 |
| Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence panitumumab, cisplatin, fluorouracil - Head and Neck Cancer | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2012-01-16 | ||
| Phase II Trial of Allovectin-7® for Head and Neck Cancer Allovectin-7® - Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx | Phase 3 | Completed | Vical | 2008-06-24 |
Tongue Neoplasms (10) · Head and Neck Neoplasms (9) · Squamous Cell Carcinoma of Head and Neck (8) · Salivary Gland Neoplasms (3) · Esthesioneuroblastoma, Olfactory (2) · Carcinoma (1) · Glossitis, Benign Migratory (1) · Hypopharyngeal Neoplasms (1) · Infections (1) · Laryngeal Diseases (1) · Laryngeal Neoplasms (1) · Lip Neoplasms (1) · Lymphoid Interstitial Pneumonia (1) · Malnutrition (1) · Mouth Neoplasms (1)
Mouth Diseases (11) · Stomatognathic Diseases (11) · Neoplasms by Site (10) · Mouth Neoplasms (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Carcinoma, Squamous Cell (8) · Carcinoma (7) · Salivary Gland Diseases (3) · Cranial Nerve Diseases (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2)
Chemotherapy, Adjuvant (2) · Cisplatin (2) · Fluorouracil (2) · Radiotherapy, Intensity-Modulated (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Allovectin-7 (1) · Bevacizumab (1) · Carboplatin (1) · Cetuximab (1) · Disulfides (1) · Docetaxel (1) · Doxepin (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Neoadjuvant Therapy (1)
Radiation Therapy Oncology Group (2) · Alliance for Clinical Trials in Oncology (1) · Centre Antoine Lacassagne (1) · European Institute of Oncology (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Marilyn Dodd (1) · National Cancer Institute (NCI) (1) · University Medical Centre Ljubljana (1) · Vical (1) · Warwick Medical School (1)
United States (6) · Canada (2) · China (1) · France (1) · Italy (1) · Puerto Rico (1) · Saudi Arabia (1) · Slovenia (1) · South Africa (1) · United Kingdom (1)
Carla Van Herpen (1) · Giorgio Cortesina, MD (1) · Hans Langendijk (1) · Hisham Mehanna, MD (1) · Marie-Noelle Falewee Pastor (1) · Marylin J. Dodd, RN, PhD (1) · Mitchell Machtay, MD (1) · Raimond K. W. Wong, MD (1) · Robert C. Miller, MD (1) · Wilfried Budach, MD (1)
PMID 22252927, PMID 24182765, PMID 24733799, PMID 31618129, PMID 39841939
R01CA107080 (1), U10CA021115 (1), U10CA037404 (1), U10CA180820 (1), U10CA180868 (1)